Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note released on Tuesday. The brokerage issued a hold rating on the stock.

Separately, Cantor Fitzgerald restated a neutral rating and set a $3.30 price objective on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Stock Performance

Shares of Aspira Women’s Health stock opened at $2.31 on Tuesday. The stock has a market capitalization of $28.76 million, a price-to-earnings ratio of -1.59 and a beta of 1.57. Aspira Women’s Health has a 52 week low of $2.00 and a 52 week high of $6.75. The firm has a fifty day moving average of $3.13 and a two-hundred day moving average of $3.70.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Tuesday, May 21st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). The company had revenue of $2.15 million during the quarter, compared to analyst estimates of $2.10 million. Aspira Women’s Health had a negative net margin of 163.95% and a negative return on equity of 1,099.32%. During the same quarter last year, the company earned ($10.94) EPS. As a group, research analysts forecast that Aspira Women’s Health will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Aspira Women’s Health

Institutional investors have recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health by 43.1% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock worth $732,000 after acquiring an additional 53,997 shares during the period. Quantum Private Wealth LLC lifted its stake in Aspira Women’s Health by 76.8% during the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after purchasing an additional 21,788 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in shares of Aspira Women’s Health in the 3rd quarter valued at $126,000. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.